Previous 10 | Next 10 |
home / stock / mycof / mycof news
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has filed a shel...
DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly addre...
Mydecine Innovations Group press release ( OTCPK:MYCOF ): Q3 GAAP EPS of -$0.35. The company had $0.08M in cash and cash equivalents as of September 30, 2022. For further details see: Mydecine Innovations Group GAAP EPS of -$0.35
DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial result...
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that, in connection with its...
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO Canada NewsWire DENVER , Sept. 23, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ...
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Canada NewsWire DENVER , Sept. 14, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE...
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced on Thursday that it has signed an LOI to sell its digital technology subsidiary, Mindleap Health Inc. to PanGenomic Health Inc. The deal is valued at C$4 million. “We are extremely pleased with what ...
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
News, Short Squeeze, Breakout and More Instantly...
New Age Brands Company Name:
MYCOF Stock Symbol:
OTCMKTS Market:
(TheNewswire) VANCOUVER, British Columbia – TheNewswire - May 2, 2024 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has requested a temporary Management Cease Trade Orde...
(TheNewswire) VANCOUVER, British Columbia, May 2, 2024 ( The N ewswire ) — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has received a temporary Management Cease Trade O...
(TheNewswire) VANCOUVER, BC – TheNewswire - (May 1, 2024) Mydecine Innovations Group Inc . (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “ Company ” or “ Mydecine ”) announced that it has entered into certain restr...